Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
83.45
-0.69 (-0.82%)
At close: Dec 20, 2024, 4:00 PM
84.32
+0.87 (1.04%)
After-hours: Dec 20, 2024, 4:09 PM EST
Intra-Cellular Therapies Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 613.73 | 464.37 | 250.31 | 83.8 | 22.81 | 0.06 | |
| Revenue Growth (YoY) | 46.08% | 85.51% | 198.69% | 267.35% | 37537.14% | - | |
| Cost of Revenue | 263.87 | 213.89 | 155.16 | 96.88 | 67.68 | 89.12 | |
| Gross Profit | 349.86 | 250.48 | 95.16 | -13.08 | -44.86 | -89.06 | |
| Selling, General & Admin | 471.48 | 409.86 | 358.78 | 272.61 | 186.36 | 64.95 | |
| Operating Expenses | 471.48 | 409.86 | 358.78 | 272.61 | 186.36 | 64.95 | |
| Operating Income | -121.62 | -159.38 | -263.63 | -285.69 | -231.23 | -154.01 | |
| Interest & Investment Income | 36.49 | 20.34 | 7.38 | 1.57 | 4.24 | 6.29 | |
| Pretax Income | -85.13 | -139.04 | -256.25 | -284.12 | -226.99 | -147.72 | |
| Income Tax Expense | 1.24 | 0.64 | 0.01 | 0.01 | 0.01 | 0 | |
| Net Income | -86.37 | -139.67 | -256.26 | -284.13 | -227.01 | -147.72 | |
| Net Income to Common | -86.37 | -139.67 | -256.26 | -284.13 | -227.01 | -147.72 | |
| Shares Outstanding (Basic) | 101 | 96 | 94 | 81 | 70 | 55 | |
| Shares Outstanding (Diluted) | 101 | 96 | 94 | 81 | 70 | 55 | |
| Shares Change (YoY) | 5.42% | 1.95% | 15.74% | 15.47% | 27.50% | 0.87% | |
| EPS (Basic) | -0.86 | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | |
| EPS (Diluted) | -0.86 | -1.46 | -2.72 | -3.50 | -3.23 | -2.68 | |
| Free Cash Flow | -62.91 | -124.47 | -270.96 | -259.87 | -230.34 | -128.68 | |
| Free Cash Flow Per Share | -0.62 | -1.30 | -2.88 | -3.20 | -3.27 | -2.33 | |
| Gross Margin | 57.01% | 53.94% | 38.01% | -15.60% | -196.66% | - | |
| Operating Margin | -19.82% | -34.32% | -105.32% | -340.90% | -1013.58% | -254090.46% | |
| Profit Margin | -14.07% | -30.08% | -102.37% | -339.04% | -995.07% | -243713.69% | |
| Free Cash Flow Margin | -10.25% | -26.80% | -108.25% | -310.10% | -1009.69% | -212303.69% | |
| EBITDA | -121.09 | -158.85 | -262.97 | -285.16 | -230.7 | -153.53 | |
| EBITDA Margin | -19.73% | -34.21% | -105.06% | - | - | - | |
| D&A For EBITDA | 0.54 | 0.53 | 0.66 | 0.53 | 0.53 | 0.48 | |
| EBIT | -121.62 | -159.38 | -263.63 | -285.69 | -231.23 | -154.01 | |
| EBIT Margin | -19.82% | -34.32% | -105.32% | - | - | - | |
| Revenue as Reported | 613.73 | 464.37 | 250.31 | 83.8 | 22.81 | 0.06 | |
| Advertising Expenses | - | 92.2 | 85.8 | 82.5 | 36.3 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.